GBL
GBL is an industrial solvent that the body converts into GHB; it is a depressant with the same dangers as GHB — overdose, dependence, and lethal interaction with alcohol — and acts faster.
Overview
GBL (gamma-butyrolactone) is an industrial chemical and solvent that the body rapidly converts into GHB after it is swallowed, so its effects are essentially those of GHB. Because of this, GBL is used as a 'prodrug' substitute for GHB and carries all the same dangers, with some made worse: GBL is absorbed faster and is more potent by volume than GHB, so the margin between a recreational amount and a dangerous one is even narrower and harder to judge. Like GHB it is a central nervous system depressant, it has a steep dose-response curve, it is strongly associated with dependence, and it is extremely dangerous in combination with alcohol. It is encountered as a liquid and is sometimes sold under the guise of its industrial uses.
Source: DEA; EMCDDA; PubChem CID 7302
Chemistry & mechanism of action
GBL itself is largely inactive until the body converts it — quickly, via enzymes in the blood and tissues — into GHB, which is the actual active drug. GHB then acts as a central nervous system depressant, affecting GABA-B and dedicated GHB receptors to produce sedation and, at higher doses, deep unconsciousness and suppression of breathing. Because GBL is converted rapidly and is absorbed faster than GHB, its effects come on quicker and the dose needed is smaller, which makes accidental overdose easier. The same depressant mechanism is why combining it with other depressants — above all alcohol — is so dangerous. Repeated use produces tolerance and a physical dependence whose withdrawal can be severe.
Source: DEA; PubChem CID 7302
Effects
Because it becomes GHB in the body, GBL produces the same effects: at lower doses, relaxation, euphoria, reduced inhibition, and sociability; as the dose rises, drowsiness, dizziness, nausea, confusion, and loss of coordination. The crucial problem is the steep, unpredictable dose-response — a small increase in amount can tip a person from a recreational effect into deep sedation, unconsciousness, dangerously slowed breathing, and coma. Because GBL is more potent by volume and faster-acting than GHB, this transition can happen quickly and with very small differences in dose. Repeated use leads to tolerance and dependence, and frequent users can develop a severe withdrawal syndrome when they stop.
Source: DEA; EMCDDA
Risks & harms
GBL carries all of GHB's dangers, several intensified. The dose-response curve is steep and unpredictable, and because GBL is more potent by volume and faster-acting, the gap between a desired effect and overdose is very narrow — overdose can bring deep unconsciousness, dangerously slowed breathing, vomiting with a risk of choking, seizures, and coma. The single most dangerous combination is with alcohol (or other depressants): together they multiply the suppression of breathing and have caused many deaths. There is no reversal agent; an overdose is a medical emergency requiring 911 and careful airway management — someone who is heavily sedated should never be left alone to 'sleep it off,' and should be placed on their side to reduce choking risk. Heavy regular use produces physical dependence, and GBL/GHB withdrawal can be severe and medically dangerous — including agitation, confusion, and seizures — and should be managed with medical support, not stopped abruptly alone. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: DEA; EMCDDA; SAMHSA
Legal status (US)
In the United States, GBL is controlled as a List I chemical and, because it is a recognized GHB analogue that converts to GHB in the body, it can be treated as a controlled substance analogue (subject to Schedule I-style treatment) when intended for human consumption. GHB itself is Schedule I (with the prescription medicine Xyrem in Schedule III). Selling or possessing GBL for people to ingest is therefore illegal, even though GBL has legitimate industrial uses. Internationally, GBL is controlled or restricted in many countries, often specifically because of its conversion to GHB. For country-by-country legal detail, see our legality pages.
Source: DEA; EMCDDA
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With depressants, the danger is over-sedation: if someone is very drowsy, hard to wake, or breathing slowly, treat it as an emergency.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 7302PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- oxolan-2-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C4H6O2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- C1CC(=O)OC1PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- YEJRWHAVMIAJKC-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- blue nitro, gamma-Butyrolactone, BUTYROLACTONE, dihydrofuran-2(3H)-one, 4-Butyrolactone, 4-Butanolide, 1,4-Butanolide, 4-Hydroxybutyric acid lactone, 2-Oxolanone, Dihydro-2(3H)-furanone, oxolan-2-onePubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review
- Route
- Unknown — pending review
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA ↗ · retrieved 2026-06-18
Effects
- Effects
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Risks
- Risks
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Interactions
- Interactions
- See DailyMed label §Drug Interactions (Rx) — synthesize + cite per itemDailyMed SPL §Drug Interactions ↗ · retrieved 2026-06-18
Dosage
Pending medical reviewer
